Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00468117 · ClinicalTrials.gov registry record · Phase 3

Efficacy of Islet After Kidney Transplantation

A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 3
Development phase
24
Enrollment target
10
Study locations

NCT00468117 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00468117, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 3
Development phase
24 participants
Enrollment target
10
Study locations

Study Summary

Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the benefit of islet transplantation in type 1 diabetic (T1D) kidney transplant recipients.

Conditions Studied

Type 1 Diabetes Mellitus

Interventions

  • BIOLOGICAL Etanercept
  • PROCEDURE Islet transplantation
  • BIOLOGICAL Antithymocyte Globulin
  • BIOLOGICAL Daclizumab or Basiliximab
  • BIOLOGICAL Allogenic human purified pancreatic islets

Study Locations (10)

Illinois

  • Northwestern University - Chicago
  • University of Illinois at Chicago - Chicago

California

  • University of California, San Francisco - San Francisco

Florida

  • University of Miami - Miami

Georgia

  • Emory Universtiy - Atlanta

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • University of Minnesota - Minneapolis

Pennsylvania

  • University of Pennsylvania - Philadelphia

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2007-01
Est. Completion 2017-07-05
Phase Phase 3

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00468117

The ClinicalTrials.gov registry entry for NCT00468117 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (83% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 5 interventions - of which Etanercept is the first listed.

NCT00468117 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Illinois, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00468117 about?

NCT00468117 is a clinical study titled "Efficacy of Islet After Kidney Transplantation". Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the benefit of islet transplantation in type 1 diabetic (T1D) kidney transplant recipients.

What is the current status of trial NCT00468117?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2007-01. Estimated completion is 2017-07-05.

What conditions does trial NCT00468117 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT00468117?

The interventions under investigation include: Etanercept (BIOLOGICAL), Islet transplantation (PROCEDURE), Antithymocyte Globulin (BIOLOGICAL), Daclizumab or Basiliximab (BIOLOGICAL), Allogenic human purified pancreatic islets (BIOLOGICAL).

Who is sponsoring clinical trial NCT00468117?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00468117 being conducted?

This trial has 10 study locations across California, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes Mellitus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.